Breaking News on Today’s Bold Stock:

MZEI Breaking News – A Break-though in Fighting MRSA:

MRSA Breakthrough announced for the AsepticSure™ Hospital Sterilization System

Publisher’s Note: This is huge. See highlighted section.

San Francisco, California, Medizone International, Inc. (MZEI.OB) announces that following several months of research, AsepticSure™ can now achieve a level of bacterial decontamination heretofore unseen in open space settings using conventional means. Dr Michael E. Shannon, Director of Medical Affairs, Medizone International stated, “our research team has pressed hard over the last few months to systematically evaluate various decontamination options involving numerous technological approaches in combination, and to our surprise, we have managed reliably and predictably to break through the 6 log barrier with MRSA. This unexpected development will significantly expand the utility for AsepticSure™, since by definition, any bacterial reduction beyond 6 logs (99.9999%) is considered STERILIZATION. This unique combination of technologies and protocols will now be tested on C difficile, E coli, Pseudomonas aeruginous, and VRE with the expectation that AsepticSure™ will achieve the same degree of incremental improvement over the 4 to 5 log reductions we have already demonstrated with those pathogens in earlier trials.”

Medizone International is preparing a second patent filing to cover these developments while construction and instrumentation of an expanded laboratory setting at the company’s Innovation Park, Queens University laboratory continues in preparation for full room scale-up testing of its equipment to commence in December.

Medizone International, Inc., is a research and development company engaged in developing its’

AsepticSure™ technology to decontaminate and sterilize hospital surgical suites, emergency rooms,

intensive care units, schools and other critical infrastructure. Current trials are now being expanded to include a hospital mock-up to be followed by hospital beta testing. Initial sales are targeted to commence early in 2010.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

Investor Relations: 415-868-0300 / web site: www.medizoneint.com

E-mail: [email protected]

Our Earlier Alert:

OTCBB: MZEI

Why Medizone International?:

Dear Bold Members:

This is a stock I know well and have put a lot of time into the past nearly six months. I am a believer in the company. I am a believer in the people behind the company. And – most importantly – I am a believer in the product that is coming. Over the next few days I will be telling you more. Here is a quick synopses:

What problem does their product solve?

The Silent Epidemic

The chart you see above represents the Nosocomial infections outside intensive care units for U.S. hospitals in 2002.

As the notes that came from the source for this chart point out, Nosocomial infections are a huge problem in hospitals today. Although this data is from 2002, the situation has progressively become more serious. Here are the notes that accompanied the chart:

“From the total number of surgical site infections (SSI) obtained from the National Hospital Discharge Dataset and the National Nosocomial Infections Surveillance (NNIS) system, we subtracted the number of SSI among newborns and adults and children in intensive care units. The remaining SSI were among adults and children outside of intensive care units. From hospital-wide surveillance in NNIS, we had the distribution of infectons by major site and calculated the corresponding number of infections for pneumonias (PNEU), urinary tract infections (UTI), bloodstream infections (BSI), and other sites.”

The Impact of Nosocomial Infections in The United States

In 2002, there were approximately 1.7 million total infections. Of these:

• 33,269 occurred among newborns in high-risk nurseries
• 19,059 among newborns in well-baby nurseries
• 417,946 among adults and children in ICUs
• 1,266,851 among adults and children outside of ICUs.

In that year, the estimated deaths in U.S. hospitals were 98,987. Of these:

• 35,967 were for pneumonia
• 30,665 for bloodstream infections
• 13,088 for urinary tract infections
• 8,205 for surgical site infections, and
• 11,062 for infections of other sites.[1]

Nosocomial Infections are an International Problem

In a World Health Organization Survey of 55 hospitals in 14 countries representing four regions, an average 8.7% of hospital patients had nosocomial infections.

What are some of these Infections?

Here is a short list: C-difficile, E-coli, Pseudomonas aeruginous, MRSA and VRE, the main causative agents of hospital derived nosocomial infections.

How bad are some of these?

C. Difficile

C. Difficile is the most serious cause of antibiotic-associated diarrhea (AAD) and can lead to pseudomembranous colitis, a severe infection of the colon, often resulting from eradication of the normal gut flora by antibiotics. Some estimates place the added cost to the healthcare for C. Difficile alone at $17.6 million daily. The CDC estimates that C. Difficile ases in the US may reach 500,000 annually leading to potentially 30,000 deaths.

MRSA

Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium responsible for difficult-to-treat infections in humans. MRSA are by definition strains of Staphylococcus aureus that are resistant to a large group of antibiotics called the beta-lactams. CDC reported (JAMA, 2007) that the number of serious infections by MRSA in 2006 was close to 100,000, with approximately 19,000 associated deaths.

What is their product?

A Solution: Ozone is a Prime Candidate for use as a Sterilization Agent in Medical Facilities

Many people do not realize that ozone had a long and successful history of use as a potent anti-bacterial, anti-fingal and anti-viral agent. Ozone was first used as a disinfectant in 1881 by Dr. Kellog. In 1893 Ozone was used in the Netherlands for water purification. Presently, in excess of 3,000 municipalities around the world use Ozone for water purification.

Research conducted in New York City has also demonstrated that Ozone is effective against Legionella Bacteria, as well as pseudomonas populations in those water purification plants. Ohio State University (2001) demonstrated a 4 log difference in sporicidal action of Ozone vs. Vaporized Hydrogen Peroxide (6.1 log reduction for Ozone vs. 1.6 log reduction for VHP). Microsearch Laboratories has demonstrated (2007) that Ozone is 3,200 times more effective than chlorine.

Maturity of the stock price… What is the time horizon?

I think the full potential here will not be realized for about three to six months. That said, when you look at what the company is doing and how well it is doing it, you have to think they will have a great market..

Thanks,

Mr. Bold

Get BOLD STOCKS on TWITTER:

http://twitter.com/boldstocks

Get The BOLD STOCKS RSS FEED:

http://www.boldstocks.com/feed/

To stop receiving these emails please unsubscribe.
Type your Company Name,Bold Stocks (”Bold”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on our web site, www.BoldStocks.com. Bold utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by Bold to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Bold encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Bold makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bold is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.boldstocks.com or mentioned herein. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bold undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage. When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future. Compensation is typically in cash. Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. MZEI Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.